Health & Fitness
Tue, April 9, 2013Mon, April 8, 2013Sat, April 6, 2013Fri, April 5, 2013Thu, April 4, 2013Wed, April 3, 2013Tue, April 2, 2013Mon, April 1, 2013Fri, March 29, 2013Thu, March 28, 2013Wed, March 27, 2013Tue, March 26, 2013Mon, March 25, 2013Sun, March 24, 2013Fri, March 22, 2013Thu, March 21, 2013Wed, March 20, 2013Tue, March 19, 2013Mon, March 18, 2013Sun, March 17, 2013Fri, March 15, 2013Thu, March 14, 2013Wed, March 13, 2013Tue, March 12, 2013International Stem Cell Corporation to Host Conference Call Thursday, March 28 to Discuss Year End 2012 Financial Results and P
Published in Health and Fitness on Tuesday, March 26th 2013 at 5:16 GMT by Market Wire
March 26, 2013 08:00 ET
International Stem Cell Corporation to Host Conference Call Thursday, March 28 to Discuss Year End 2012 Financial Results and Provide Business Update
CARLSBAD, CA--(Marketwire - Mar 26, 2013) - International Stem Cell Corporation (
Dr. Simon Craw, Executive Vice President and Ms. Linh Nguyen, Chief Financial Officer of International Stem Cell, will host the conference call. To attend the call, please use the dial in information below:
Date: Thursday March 28, 2013
Time: 11:00 a.m. ET
Conference Line (U.S.): 1-877-941-2068
International Dial-In: 1-480-629-9712
Conference ID: 4610666
Webcast: [ http://public.viavid.com/player/index.php?id=104040 ]
Please log in at least 10 minutes before the call start time to ensure timely participation.
A playback of the call will be available from 2:00 p.m. ET on March 28, 2013 to 11:59 p.m. ET on April 11, 2013.
Teleconference Replay Details:
US Domestic: 1-877-870-5176
International: 1-858-384-5517
Conference ID: 4610666
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology ([ www.lifelinecelltech.com ]), and stem cell-based skin care products through its subsidiary Lifeline Skin Care ([ www.lifelineskincare.com ]). More information is available at [ www.internationalstemcell.com ].
To receive ongoing corporate communications via email, visit: [ http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 ]
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: [ www.facebook.com/InternationalStemCellCorporation ] and [ www.twitter.com/intlstemcell ]
